Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Human Papillomarirus Type 16 ¹× 18¿¡ °¨¿°µÈ ÀڱðâºÎ¾Ï ȯÀÚ¿¡¼­ Proliferating Cell Nuclear Antigen ÃøÁ¤¿¡ °üÇÑ ¿¬±¸ The Assessment of Proliferating Cell Nuclear Antigen(PCNA) in Cervical Carcinoma Patients Infected with Human Papillomavirus Types 16 and 18

´ëÇѾÏÇÐȸÁö 1995³â 27±Ç 5È£ p.773 ~ 782
±èÁö¿¬, ÀÌÁ¾ÈÆ, ±èÁعü, ÃÖÀç±Ô,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÁö¿¬ (  ) 
°Ç±¹´ëÇб³

ÀÌÁ¾ÈÆ (  ) 
°Ç±¹´ëÇб³
±èÁعü (  ) 
°Ç±¹´ëÇб³
ÃÖÀç±Ô (  ) 
°Ç±¹´ëÇб³

Abstract


Proliferating cell nuclear antigen (PCNA) is a nuclear protein associated with the cell proliferative state. The relationship between the presence of human papillomavirus (HPV) and proliferative indices (PI) was studied. Determination of PI was
done by
immunohistochemical staining via the avidin-biotin-complex immunoperoxidase method and HPV 16 and HPV 18 status by Southern blot hybridization on paraffin-embedded material from 49 patients with carcinoma of the uterine cervix.
HPV 16 was present in 15 cases, HPV 18 was observed in 6 cases, and both HPV 16 and HPV 18 were found in 4 cases. There was significant correlation between PI and HPV types. PI was 59.7¡¾9.0% in HPV 16 positive lesion, 67.4¡¾10.0% in HPV 18
positive
lesion, 79.4¡¾4.2% in both HPV 16 and HPV 18 positive lesion, and 57.5¡¾16.9% in HPV negative lesion.
Among cervical adenocarcinomas, PI was 72.5¡¾14.9% in HPV 16 or HPV 18positive lesion, as compared to 39.8¡¾15.1% in HPV negative lesion. No correlation was found between HPV-DNA positivity and PI in relation to clinical stages, histologic types,
and
lesion size.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS